Complement activation profiles in patients with immune checkpoint inhibitor-associated neuromuscular immune-related adverse events
Journal of Neurology · 2025
DOI: 10.1007/s00415-025-13181-2 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Neurology, 2025. Verfasst von Leonie Müller-Jensen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-U…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Complement Activation, Myositis, Peripheral Nervous System Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Else Kröner-Fresenius-Stiftung, Berlin Institute of Health, Medizinischen Hochschule Hannover.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Immune-related neuropathy (irNeuropathy) and myositis (irMyositis) are the most common neurologic adverse events (irAE-n) associated with immune checkpoint inhibitors. Although case reports suggest benefits of complement inhibitors, the role of complement activation in irAE-n is understudied.
Methods
In a retrospective multicenter study, we enrolled patients with irNeuropathy or irMyositis, cancer controls (CCs), and healthy controls (HCs). Serum levels of 11 complement components were measured using multiplex enzyme-linked immunosorbent assays. Associations with irAE-n severity and outcomes were assessed by Spearman’s correlation. C5b-9-positive complement deposition was analyzed in muscle and nerve specimens from a subset of patients.
Results
Thirty-one irMyositis patients, 25 irNeuropathy patients, 25 CCs, and 17 HCs were included. Complement component levels were elevated in irNeuropathy (C3a, C5a, sC5b-9, C3, Ba, C4a), irMyositis (C3a, Ba), and CCs (C3a, C5a, sC5b-9, Bb, Ba, C4a), compared to HCs. In irMyositis, higher levels of C5a and complement regulators Factor H and I correlated with lower irAE-n severity ( p = 0.02, rho = −0.45; p = < 0.01, rho = −0.56; p = < 0.001, rho = −0.67, respectively), and improved outcomes ( p = 0.03, rho = −0.42; p = 0.05, rho = −0.40; p = < 0.001, rho = −0.64, respectively). Subtle C5b-9 deposition was detected in all tissue samples but showed non-specific patterns.
Discussion
Systemic complement activation is detectable in cancer patients regardless of irAE-n status, and tissue complement deposition is unspecific. Our findings suggest that complement activation is not a major driver of irAE-n, leaving the therapeutic potential of complement inhibitors uncertain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.…
- Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany. leonie.mueller-jensen@charite.de.
- Department of Neurology, Hannover Medical School, 30625, Hannover, Germany.
- Immune Cooperative Oncology Group, Comprehensive Cancer Center Hannover (ICOG-CCCH), Hannover, Germany.
- Department of Hematology, Hemostaseology and Oncology, Hannover Medical School, 30625, Hannover, Germany.
- Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, 30625, Hannover, Germany.
Förderung
- Else Kröner-Fresenius-Stiftung
- Berlin Institute of Health
- Medizinischen Hochschule Hannover
- Charité - Universitätsmedizin Berlin
Zitieren
APA
Müller-Jensen, L., Möhn, N., Skripuletz, T., Carl, S., Thomas, J., Grote-Levi, L., Nay, S., Ivanyi, P., von Wasielewski, I., Gutzmer, R., Dittmayer, C., Stenzel, W., Knauss, S., Endres, M., Lünemann, J. D., Boehmerle, W., & Huehnchen, P. (2025). Complement activation profiles in patients with immune checkpoint inhibitor-associated neuromuscular immune-related adverse events. Journal of Neurology. https://doi.org/10.1007/s00415-025-13181-2
Vancouver
Müller-Jensen L, Möhn N, Skripuletz T, Carl S, Thomas J, Grote-Levi L, et al. Complement activation profiles in patients with immune checkpoint inhibitor-associated neuromuscular immune-related adverse events. Journal of Neurology. 2025. doi:10.1007/s00415-025-13181-2
BibTeX
@article{MllerJensen2025,
author = {Müller-Jensen, Leonie and Möhn, Nora and Skripuletz, Thomas and Carl, Sophia and Thomas, Janin and Grote-Levi, Lea and Nay, Sandra and Ivanyi, Philipp and von Wasielewski, Imke and Gutzmer, Ralf and Dittmayer, Carsten and Stenzel, Werner and Knauss, Samuel and Endres, Matthias and Lünemann, Jan D and Boehmerle, Wolfgang and Huehnchen, Petra},
title = {Complement activation profiles in patients with immune checkpoint inhibitor-associated neuromuscular immune-related adverse events},
journal = {Journal of Neurology},
year = {2025},
doi = {10.1007/s00415-025-13181-2}
}
EUVIMED